Amyotrophic Lateral Sclerosis News and Research

RSS

Scientists take important step to understand mechanisms that cause Huntington's disease

The neuroscientist Dr David Vilchez and his team at CECAD, the University of Cologne's Cluster of Excellence for Aging Research, have made an important step towards understanding the mechanisms that cause the neurodegenerative disorder Huntington's disease.

27 Jul 2018

Researchers gain more insight into how FUS protein causes ALS and FTLD

The mutated and aggregated protein FUS is implicated in two neurodegenerative diseases: amyotrophic lateral sclerosis and frontotemporal lobar degeneration.

19 Jul 2018

Researchers identify new compound that protects against neurodegeneration

Researchers from the University of Liverpool have identified a new compound that protects against neurodegeneration in nematode worms. The discovery may enable novel treatments for human neurodegenerative diseases to be developed in the future.

18 Jul 2018

Researchers discover prion-like viral proteins that open new targets for antiviral drugs

Researchers at the Human Microbiology Institute and Tetz Laboratories have discovered thousands of prion-like domains in human viruses, prompting research that opens new ways of viral pathogenicity, suggests new targets for development of new antiviral drugs and links viruses to diseases such as Alzheimer’s and Parkinson’s.

12 Jul 2018

Targeting multiple proteins may be key to treat neurodegenerative disorders

Nearly all major neurodegenerative diseases - from Alzheimer's to Parkinson's - are defined and diagnosed by the presence of one of four proteins that have gone rogue: tau, amyloid-beta, alpha-synuclein, or TDP-43.

6 Jul 2018

Study finds that several existing anti-cancer drugs may work in part by binding to RNA

Bolstering the notion that RNA should be considered an important drug-discovery target, scientists at Scripps Research have found that several existing, FDA-approved anti-cancer drugs may work, in part, by binding tightly to RNA, the regulators of the basic activities of life within cells.

30 Jun 2018

UC Riverside researcher receives grants to advance cancer, ALS research

Maurizio Pellecchia, who holds the Daniel Hays Chair in Cancer Research at the University of California, Riverside, has received two grants to continue his research aimed at finding therapeutics for cancer, amyotrophic lateral sclerosis, and other neurodegenerative diseases.

21 Jun 2018

Aquinnah Pharmaceuticals wins NINDS grant to advance novel therapies for ALS

Aquinnah Pharmaceuticals, leaders in stress granule biology, an exciting new target for the development of neurodegenerative therapeutics, announced today that it has been awarded $3.4 million from the National Institute of Neurological Disorders and Stroke in a competing grant to advance novel therapeutic drug candidates towards the clinic for treating patients with amyotrophic lateral sclerosis, also known as Lou Gehrig's disease.

21 Jun 2018

Study unravels how nuclear pore complexes transport mRNAs out of the nucleus

Standing guard between a cell's nucleus and its main chamber, called the cytoplasm, are thousands of behemoth protein structures called nuclear pore complexes, or NPCs.

13 Jun 2018

Study could open up new treatment approaches for neurodegenerative diseases

Cell biologists have deepened understanding of proteins associated with neurodegenerative diseases. The findings could open up new treatment approaches for disorders including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (ALS), among others.

31 May 2018

Researchers seek new approaches to better protect the eye from glaucoma

Under the increased pressure of glaucoma, scientists want to help the neurons in our eyes better protect themselves and get better help from their friends.

29 May 2018

Researchers work together to solve mystery of motor neuron death in ALS patients

As the old adage goes, 'two heads are better than one'. With the development of new technologies and increasingly specialist expertise, ground-breaking science needs to be a team effort.

25 May 2018

Scientists report new strategy for fighting bacteria

Antimicrobial resistance is a major medical problem worldwide, impacting both human health and economic well-being.

24 May 2018

Study identifies new mechanism involved in development of Lou Gehrig's disease

A new Tel Aviv University study identifies a previously unknown mechanism involved in the development of Lou Gehrig's disease, or amyotrophic lateral sclerosis.

23 May 2018

Small part of cellular protein that helps form long-term memories also drives neurodegeneration

Scientists have just discovered that a small region of a cellular protein that helps long-term memories form also drives the neurodegeneration seen in Amyotrophic Lateral Sclerosis (ALS). This small part of the Ataxin-2 protein thus works for good and for bad.

23 May 2018

Schizophrenics' blood samples feature genetic material from more types of microorganisms

The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found.

22 May 2018

Treg infusions show promise in slowing progression of ALS

Recent research from Houston Methodist Hospital showed that a new immunotherapy was safe for patients with ALS and also revealed surprising results that could bring hope to patients who have this relentlessly progressive and fatal disease.

21 May 2018

New study could have important implications for cellular aging

Researchers have found a way to stimulate autophagy, a process used by cells to convert misfolded proteins and redundant organelles into components that the cell can re-use.

16 May 2018

Phase 2 study of dexpramipexole in hypereosinophilic syndromes meets its co-primary endpoints

Knopp Biosciences LLC today announced the publication of a report in the journal Blood that a Phase 2 study of dexpramipexole in hypereosinophilic syndromes met its co-primary endpoints.

10 May 2018

FDA seeks order of permanent injunction to stop two stem cell clinics from marketing stem cell products

The U.S. Food and Drug Administration, in two complaints filed today in federal court, is seeking permanent injunctions to stop two stem cell clinics from marketing stem cell products without FDA approval and for significant deviations from current good manufacturing practice requirements.